Neurosteroid [3α,5α]-3-Hydroxy-pregnan-20-one Enhances the CX3CL1-CX3CR1 Pathway in the Brain of Alcohol-Preferring Rats with Sex-Specificity
<p>(<b>a</b>) 3α,5α-THP upregulates the levels of CX3-C motif chemokine ligand 1/fractalkine (CX3CL1) in the nucleus accumbens (NAc) of female, but not male alcohol-preferring (P) rats. Male and female P rats (n = 10/group) were treated intraperitoneally with 3α,5α-THP (10 mg/kg) or vehicle (45% <span class="html-italic">w</span>/<span class="html-italic">v</span> 2-hydroxypropyl-β-cyclodextrin) control. After 60 min, the nucleus accumbens (NAc) was examined using ELISA to determine CX3CL1 expression. In females, the administration of 3α,5α-THP resulted in a significant increase in CX3CL1 levels within the NAc (<span class="html-italic">p</span> = 0.02). However, in male rats, 3α,5α-THP treatment did not lead to a notable change in CX3CL1 expression within the NAc (<span class="html-italic">p</span> = 0.91). In the graphs, every column, along with its error bar, represents the mean ± SEM, expressed in pg/mg of total protein level. Each circle represents an individual CX3CL1 value for vehicle-treated rats, while the black squares indicate the CX3CL1 values for the 3α,5α-THP-treated rats. * <span class="html-italic">p</span> < 0.05. (<b>b</b>) Qualitative evaluation of 3α,5α-THP’s impact on the intracellular distribution of CX3CL1 in the NAc of female P rats. Double-immunofluorescent staining was conducted using antibodies targeting CX3CL1 alongside NeuN (a neuronal marker), TMEM119 (a microglial marker) or GFAP (an astrocyte marker). In vehicle control, CX3CL1 was observed to localize within NeuN-positive neuronal cells while not co-localizing with TMEM119-positive microglial cells or GFAP-positive astrocytic cells. Treatment with 3α,5α-THP did not induce any evident alterations in CX3CL1’s intracellular localization. Scale bar is 50 µm.</p> "> Figure 2
<p>3α,5α-THP enhances CX3CR1 levels in the nucleus accumbens (NAc) of female P rats, but not in males. Male and female alcohol-preferring (P) rats (n = 10/group) were treated intraperitoneally with 3α,5α-THP (10 mg/kg) or vehicle (45% <span class="html-italic">w</span>/<span class="html-italic">v</span> 2-hydroxypropyl-β-cyclodextrin) control. After 60 min, the NAc was examined using immunoblotting assays to determine CX3CR1 expression. Specifically, in females, administering 3α,5α-THP resulted in a significant elevation of CX3CR1 levels within the NAc (<span class="html-italic">p</span> = 0.0006). Conversely, in male rats, treatment with 3α,5α-THP did not induce a noteworthy alteration in CX3CR1 expression within the NAc (<span class="html-italic">p</span> = 0.98). In the graphs, every column, along with its error bar, represents the mean ± SEM, expressed as a percentage relative to the average value of the vehicle control. Each circle represents an individual CX3CR1 value, normalized to β-Actin for vehicle-treated rats, while the black squares indicate the corresponding values for the 3α,5α-THP-treated rats. *** <span class="html-italic">p</span> < 0.001.</p> "> Figure 3
<p>3α,5α-THP upregulates the levels of pSTAT1 in the nucleus accumbens (NAc) of female, but not male P rats. Male and female alcohol-preferring (P) rats (n = 10/group) were treated intraperitoneally with 3α,5α-THP (10 mg/kg) or vehicle (45% <span class="html-italic">w</span>/<span class="html-italic">v</span> 2-hydroxypropyl-β-cyclodextrin) control. After 60 min, the NAc was examined using immunoblotting assays to determine pSTAT1 expression. In females, the administration of 3α,5α-THP resulted in a significant increase in pSTAT1 levels within the NAc (<span class="html-italic">p</span> = 0.0002). However, in male rats, 3α,5α-THP treatment did not lead to a notable change in pSTAT1 expression within the NAc (<span class="html-italic">p</span> = 0.08). In the graphs, every column, along with its error bar, represents the mean ± SEM, expressed as a percentage relative to the average value of the vehicle control. Each circle represents an individual pSTAT1 value, normalized to β-Actin for vehicle-treated rats, while the black squares indicate the corresponding values for the 3α,5α-THP-treated rats. *** <span class="html-italic">p</span> < 0.001.</p> "> Figure 4
<p>3α,5α-THP upregulates the levels of TGF-β1 in the nucleus accumbens (NAc) of female, but not male P rats. Male and female alcohol-preferring (P) rats (n = 10/group) were treated intraperitoneally with 3α,5α-THP (10 mg/kg) or vehicle (45% <span class="html-italic">w</span>/<span class="html-italic">v</span> 2-hydroxypropyl-β-cyclodextrin) control. After 60 min, the NAc was examined using immunoblotting assays to determine TGF-β1 expression. In females, the administration of 3α,5α-THP (10 mg/kg, IP) resulted in a significant increase in TGF-β1 levels within the NAc (<span class="html-italic">p</span> = 0.04). However, in male rats, 3α,5α-THP treatment did not lead to a notable change in TGF-β1 expression within the NAc (<span class="html-italic">p</span> = 0.21). In the graphs, every column, along with its error bar, represents the mean ± SEM, expressed as a percentage relative to the average value of the vehicle control. Each circle represents an individual TGF-β1 value, normalized to β-Actin for vehicle-treated rats, while the black squares indicate the corresponding values for the 3α,5α-THP-treated rats. * <span class="html-italic">p</span> < 0.05.</p> "> Figure 5
<p>3α,5α-THP downregulates the levels of the astrocytic marker GFAP in the nucleus accumbens (NAc) of female and male P rats. Male and female alcohol-preferring (P) rats (n = 10/group) were treated intraperitoneally with 3α,5α-THP (10 mg/kg) or vehicle (45% <span class="html-italic">w</span>/<span class="html-italic">v</span> 2-hydroxypropyl-β-cyclodextrin) control. After 60 min, the NAc was examined using immunoblotting assays to determine GFAP expression. In both females (<span class="html-italic">p</span> = 0.02) and males (<span class="html-italic">p</span> = 0.03), administering 3α,5α-THP led to a significant decrease in GFAP levels within the NAc. In the graphs, every column, along with its error bar, represents the mean ± SEM, expressed as a percentage relative to the average value of the vehicle control. Each circle represents an individual GFAP value, normalized to β-Actin for vehicle-treated rats, while the black squares indicate the corresponding values for the 3α,5α-THP-treated rats. * <span class="html-italic">p</span> < 0.05.</p> "> Figure 6
<p>Schematic of 3α,5α-THP (allopregnanolone) actions on CX3CL1/CX3CR1 signaling in the brain of female ethanol-naïve alcohol-preferring (P) rats. Initially, activation of inflammatory TLR pathways leads to the upregulation of inflammatory factors, resulting in decreased levels (red arrows down) of CX3CL1 in neurons and CX3CR1 in glia, thereby reducing (black double-ended arrows crossed by a red zigzag) CX3CL1/CX3CR1 signaling between neurons and glia. Concurrently, GFAP upregulation (red arrow up) in astrocytes also contributes to disrupted neuron–glial communication. Upon administration of 3α,5α-THP, inflammatory TLR pathways are inhibited, resulting in the downregulation of inflammatory factors. Subsequently, CX3CL1 levels in neurons increase (green arrow up) through the activation (phosphorylation) of STAT1 (pSTAT1 upregulation is represented by a green arrow up), while CX3CR1 levels in glia are upregulated (green arrow up) via TGF-β1 (TGF-β1 upregulation is represented by a green arrow up) involvement. Additionally, GFAP levels in astrocytes decrease (green arrow down). These changes ultimately lead to enhanced neuron–glial communication (black double-ended arrows). Created with BioRender.com.</p> ">
Abstract
:1. Introduction
2. Materials and Methods
2.1. Animals
2.2. Tissue Lysate Preparation for Immunoblotting and ELISA
2.3. Immunoblotting
2.4. ELISA
2.5. Tissue Section Preparation, Immunofluorescence Staining, and Microscopy
2.6. Antibodies
2.7. Statistics
3. Results
3.1. 3α,5α-THP Upregulates the Levels of CX3CL1 as Well as CX3CR1, pSTAT1, and TGF-β1 in the NAc of Female, but Not Male, P Rats
3.2. 3α,5α-THP Downregulates the Levels of the Astrocytic Marker GFAP but Does Not Affect Microglial Markers IBA1 and TMEM119 in the Nucleus Accumbens (NAc) of Female and Male P Rats
4. Discussion
5. Conclusions
6. Patents
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Lurie, D.I. An Integrative Approach to Neuroinflammation in Psychiatric disorders and Neuropathic Pain. J. Exp. Neurosci. 2018, 12, 1179069518793639. [Google Scholar] [CrossRef] [PubMed]
- Dunn, G.A.; Loftis, J.M.; Sullivan, E.L. Neuroinflammation in psychiatric disorders: An introductory primer. Pharmacol. Biochem. Behav. 2020, 196, 172981. [Google Scholar] [CrossRef] [PubMed]
- Najjar, S.; Pearlman, D.M.; Alper, K.; Najjar, A.; Devinsky, O. Neuroinflammation and psychiatric illness. J. Neuroinflamm. 2013, 10, 816. [Google Scholar] [CrossRef]
- Cervellati, C.; Trentini, A.; Pecorelli, A.; Valacchi, G. Inflammation in Neurological Disorders: The Thin Boundary between Brain and Periphery. Antioxid. Redox Signal. 2020, 33, 191–210. [Google Scholar] [CrossRef]
- Boero, G.; Porcu, P.; Morrow, A.L. Pleiotropic actions of allopregnanolone underlie therapeutic benefits in stress-related disease. Neurobiol. Stress 2020, 12, 100203. [Google Scholar] [CrossRef]
- Morrow, A.L.; Boero, G.; Porcu, P. A Rationale for Allopregnanolone Treatment of Alcohol Use Disorders: Basic and Clinical Studies. Alcohol. Clin. Exp. Res. 2020, 44, 320–339. [Google Scholar] [CrossRef] [PubMed]
- Morrow, A.L.; Balan, I.; Boero, G. Mechanisms Underlying Recovery From Postpartum Depression Following Brexanolone Therapy. Biol. Psychiatry 2022, 91, 252–253. [Google Scholar] [CrossRef]
- Modgil, A.; Parakala, M.L.; Ackley, M.A.; Doherty, J.J.; Moss, S.J.; Davies, P.A. Endogenous and synthetic neuroactive steroids evoke sustained increases in the efficacy of GABAergic inhibition via a protein kinase C-dependent mechanism. Neuropharmacology 2017, 113, 314–322. [Google Scholar] [CrossRef]
- Stell, B.M.; Brickley, S.G.; Tang, C.Y.; Farrant, M.; Mody, I. Neuroactive steroids reduce neuronal excitability by selectively enhancing tonic inhibition mediated by delta subunit-containing GABAA receptors. Proc. Natl. Acad. Sci. USA 2003, 100, 14439–14444. [Google Scholar] [CrossRef]
- Pinna, G. Allopregnanolone (1938–2019): A trajectory of 80 years of outstanding scientific achievements. Neurobiol. Stress 2020, 13, 100246. [Google Scholar] [CrossRef]
- Pinna, G. Allopregnanolone, the Neuromodulator Turned Therapeutic Agent: Thank You, Next? Front. Endocrinol. 2020, 11, 236. [Google Scholar] [CrossRef]
- Antonoudiou, P.; Colmers, P.L.W.; Walton, N.L.; Weiss, G.L.; Smith, A.C.; Nguyen, D.P.; Lewis, M.; Quirk, M.C.; Barros, L.; Melon, L.C.; et al. Allopregnanolone Mediates Affective Switching Through Modulation of Oscillatory States in the Basolateral Amygdala. Biol. Psychiatry 2022, 91, 283–293. [Google Scholar] [CrossRef] [PubMed]
- Balan, I.; Beattie, M.C.; O’Buckley, T.K.; Aurelian, L.; Morrow, A.L. Endogenous Neurosteroid (3⍺,5⍺)3-Hydroxypregnan-20-one Inhibits Toll-like-4 Receptor Activation and Pro-inflammatory Signaling in Macrophages and Brain. Sci. Rep. 2019, 9, 1220. [Google Scholar] [CrossRef]
- Balan, I.; Aurelian, L.; Williams, K.S.; Campbell, B.; Meeker, R.B.; Morrow, A.L. Inhibition of human macrophage activation via pregnane neurosteroid interactions with toll-like receptors: Sex differences and structural requirements. Front. Immunol. 2022, 13, 940095. [Google Scholar] [CrossRef] [PubMed]
- Langmade, S.J.; Gale, S.E.; Frolov, A.; Mohri, I.; Suzuki, K.; Mellon, S.H.; Walkley, S.U.; Covey, D.F.; Schaffer, J.E.; Ory, D.S. Pregnane X receptor (PXR) activation: A mechanism for neuroprotection in a mouse model of Niemann-Pick C disease. Proc. Natl. Acad. Sci. USA 2006, 103, 13807–13812. [Google Scholar] [CrossRef]
- Meltzer-Brody, S.; Colquhoun, H.; Riesenberg, R.; Epperson, C.N.; Deligiannidis, K.M.; Rubinow, D.R.; Li, H.; Sankoh, A.J.; Clemson, C.; Schacterle, A.; et al. Brexanolone injection in post-partum depression: Two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet 2018, 392, 1058–1070. [Google Scholar] [CrossRef] [PubMed]
- Balan, I.; Patterson, R.; Boero, G.; Krohn, H.; O’Buckley, T.K.; Meltzer-Brody, S.; Morrow, A.L. Brexanolone therapeutics in post-partum depression involves inhibition of systemic inflammatory pathways. EBioMedicine 2023, 89, 104473. [Google Scholar] [CrossRef]
- Patterson, R.; Balan, I.; Morrow, A.L.; Meltzer-Brody, S. Novel neurosteroid therapeutics for post-partum depression: Perspectives on clinical trials, program development, active research, and future directions. Neuropsychopharmacology 2024, 49, 67–72. [Google Scholar] [CrossRef] [PubMed]
- Balan, I.; Aurelian, L.; Schleicher, R.; Boero, G.; O’Buckley, T.; Morrow, A.L. Neurosteroid allopregnanolone (3alpha,5alpha-THP) inhibits inflammatory signals induced by activated MyD88-dependent toll-like receptors. Transl. Psychiatry 2021, 11, 145. [Google Scholar] [CrossRef]
- Murugan, S.; Jakka, P.; Namani, S.; Mujumdar, V.; Radhakrishnan, G. The neurosteroid pregnenolone promotes degradation of key proteins in the innate immune signaling to suppress inflammation. J. Biol. Chem. 2019, 294, 4596–4607. [Google Scholar] [CrossRef]
- Su, L.; Sun, Y.; Ma, F.; Lü, P.; Huang, H.; Zhou, J. Progesterone inhibits Toll-like receptor 4-mediated innate immune response in macrophages by suppressing NF-kappaB activation and enhancing SOCS1 expression. Immunol. Lett. 2009, 125, 151–155. [Google Scholar] [CrossRef]
- Jones, L.A.; Anthony, J.P.; Henriquez, F.L.; Lyons, R.E.; Nickdel, M.B.; Carter, K.C.; Alexander, J.; Roberts, C.W. Toll-like receptor-4-mediated macrophage activation is differentially regulated by progesterone via the glucocorticoid and progesterone receptors. Immunology 2008, 125, 59–69. [Google Scholar] [CrossRef] [PubMed]
- Zhu, Y.; Wu, M.; Wu, C.Y.; Xia, G.Q. Role of progesterone in TLR4-MyD88-dependent signaling pathway in pre-eclampsia. J. Huazhong Univ. Sci. Technol. Med. Sci. 2013, 33, 730–734. [Google Scholar] [CrossRef] [PubMed]
- Zandieh, Z.; Amjadi, F.; Ashrafi, M.; Aflatoonian, A.; Fazeli, A.; Aflatoonian, R. The Effect of Estradiol and Progesterone on Toll Like Receptor Gene Expression in A Human Fallopian Tube Epithelial Cell Line. Cell J. 2016, 17, 678–691. [Google Scholar] [CrossRef]
- Chen, G.; Shi, J.; Jin, W.; Wang, L.; Xie, W.; Sun, J.; Hang, C. Progesterone administration modulates TLRs/NF-kappaB signaling pathway in rat brain after cortical contusion. Ann. Clin. Lab. Sci. 2008, 38, 65–74. [Google Scholar] [PubMed]
- Naert, G.; Maurice, T.; Tapia-Arancibia, L.; Givalois, L. Neuroactive steroids modulate HPA axis activity and cerebral brain-derived neurotrophic factor (BDNF) protein levels in adult male rats. Psychoneuroendocrinology 2007, 32, 1062–1078. [Google Scholar] [CrossRef] [PubMed]
- Nin, M.S.; Martinez, L.A.; Pibiri, F.; Nelson, M.; Pinna, G. Neurosteroids reduce social isolation-induced behavioral deficits: A proposed link with neurosteroid-mediated upregulation of BDNF expression. Front. Endocrinol. 2011, 2, 73. [Google Scholar] [CrossRef] [PubMed]
- Almeida, F.B.; Nin, M.S.; Barros, H.M.T. The role of allopregnanolone in depressive-like behaviors: Focus on neurotrophic proteins. Neurobiol. Stress 2020, 12, 100218. [Google Scholar] [CrossRef] [PubMed]
- Harrison, J.K.; Jiang, Y.; Chen, S.; Xia, Y.; Maciejewski, D.; McNamara, R.K.; Streit, W.J.; Salafranca, M.N.; Adhikari, S.; Thompson, D.A.; et al. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc. Natl. Acad. Sci. USA 1998, 95, 10896–10901. [Google Scholar] [CrossRef]
- Tarozzo, G.; Bortolazzi, S.; Crochemore, C.; Chen, S.-C.; Lira, A.S.; Abrams, J.S.; Beltramo, M. Fractalkine protein localization and gene expression in mouse brain. J. Neurosci. Res. 2003, 73, 81–88. [Google Scholar] [CrossRef]
- Mizutani, M.; Pino, P.A.; Saederup, N.; Charo, I.F.; Ransohoff, R.M.; Cardona, A.E. The Fractalkine Receptor but Not CCR2 Is Present on Microglia from Embryonic Development throughout Adulthood. J. Immunol. 2012, 188, 29–36. [Google Scholar] [CrossRef] [PubMed]
- Maciejewski-Lenoir, D.; Chen, S.; Feng, L.; Maki, R.; Bacon, K.B. Characterization of fractalkine in rat brain cells: Migratory and activation signals for CX3CR-1-expressing microglia. J. Immunol. 1999, 163, 1628–1635. [Google Scholar] [CrossRef] [PubMed]
- Lauro, C.; Catalano, M.; Di Paolo, E.; Chece, G.; de Costanzo, I.; Trettel, F.; Limatola, C. Fractalkine/CX3CL1 engages different neuroprotective responses upon selective glutamate receptor overactivation. Front. Cell. Neurosci. 2015, 8, 472. [Google Scholar] [CrossRef] [PubMed]
- Kawamura, N.; Katsuura, G.; Yamada-Goto, N.; Nakama, R.; Kambe, Y.; Miyata, A.; Furuyashiki, T.; Narumiya, S.; Ogawa, Y.; Inui, A. Brain fractalkine-CX3CR1 signalling is anti-obesity system as anorexigenic and anti-inflammatory actions in diet-induced obese mice. Sci. Rep. 2022, 12, 12604. [Google Scholar] [CrossRef] [PubMed]
- Bérangère Ré, D.; Przedborski, S. Fractalkine: Moving from chemotaxis to neuroprotection. Nat. Neurosci. 2006, 9, 859–861. [Google Scholar] [CrossRef] [PubMed]
- Pabon, M.M.; Bachstetter, A.D.; Hudson, C.E.; Gemma, C.; Bickford, P.C. CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson’s disease. J. Neuroinflamm. 2011, 8, 9. [Google Scholar] [CrossRef] [PubMed]
- Zhao, J.; Li, Q.; Ouyang, X.; Wang, F.; Li, Q.; Xu, Z.; Ji, D.; Wu, Q.; Zhang, J.; Lu, C.; et al. The effect of CX3CL1/ CX3CR1 signal axis on microglia in central nervous system diseases. J. Neurorestoratol. 2023, 11, 100042. [Google Scholar] [CrossRef]
- Morganti, J.M.; Nash, K.R.; Grimmig, B.A.; Ranjit, S.; Small, B.; Bickford, P.C.; Gemma, C. The Soluble Isoform of CX3CL1 Is Necessary for Neuroprotection in a Mouse Model of Parkinson’s Disease. J. Neurosci. 2012, 32, 14592–14601. [Google Scholar] [CrossRef] [PubMed]
- Xiao, F.; Xu, J.M.; Jiang, X.H. CX3 chemokine receptor 1 deficiency leads to reduced dendritic complexity and delayed maturation of newborn neurons in the adult mouse hippocampus. Neural. Regen. Res. 2015, 10, 772–777. [Google Scholar] [CrossRef]
- Noda, M.; Doi, Y.; Liang, J.; Kawanokuchi, J.; Sonobe, Y.; Takeuchi, H.; Mizuno, T.; Suzumura, A. Fractalkine attenuates excito-neurotoxicity via microglial clearance of damaged neurons and antioxidant enzyme heme oxygenase-1 expression. J. Biol. Chem. 2011, 286, 2308–2319. [Google Scholar] [CrossRef]
- Meucci, O.; Fatatis, A.; Simen, A.A.; Miller, R.J. Expression of CX3CR1 chemokine receptors on neurons and their role in neuronal survival. Proc. Natl. Acad. Sci. USA 2000, 97, 8075–8080. [Google Scholar] [CrossRef] [PubMed]
- Castro-Sánchez, S.; García-Yagüe, Á.J.; López-Royo, T.; Casarejos, M.; Lanciego, J.L.; Lastres-Becker, I. Cx3cr1-deficiency exacerbates alpha-synuclein-A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson’s disease. Glia 2018, 66, 1752–1762. [Google Scholar] [CrossRef] [PubMed]
- Dorfman, M.D.; Krull, J.E.; Douglass, J.D.; Fasnacht, R.; Lara-Lince, F.; Meek, T.H.; Shi, X.; Damian, V.; Nguyen, H.T.; Matsen, M.E.; et al. Sex differences in microglial CX3CR1 signalling determine obesity susceptibility in mice. Nat. Commun. 2017, 8, 14556. [Google Scholar] [CrossRef] [PubMed]
- Cardona, S.M.; Kim, S.V.; Church, K.A.; Torres, V.O.; Cleary, I.A.; Mendiola, A.S.; Saville, S.P.; Watowich, S.S.; Parker-Thornburg, J.; Soto-Ospina, A.; et al. Role of the Fractalkine Receptor in CNS Autoimmune Inflammation: New Approach Utilizing a Mouse Model Expressing the Human CX3CR1I249/M280 Variant. Front. Cell. Neurosci. 2018, 12, 365. [Google Scholar] [CrossRef] [PubMed]
- Nash, K.R.; Moran, P.; Finneran, D.J.; Hudson, C.; Robinson, J.; Morgan, D.; Bickford, P.C. Fractalkine over expression suppresses α-synuclein-mediated neurodegeneration. Mol. Ther. 2015, 23, 17–23. [Google Scholar] [CrossRef] [PubMed]
- Paolicelli, R.C.; Bisht, K.; Tremblay, M. Fractalkine regulation of microglial physiology and consequences on the brain and behavior. Front. Cell. Neurosci. 2014, 8, 129. [Google Scholar] [CrossRef] [PubMed]
- Zujovic, V.; Benavides, J.; Vigé, X.; Carter, C.; Taupin, V. Fractalkine modulates TNF-alpha secretion and neurotoxicity induced by microglial activation. Glia 2000, 29, 305–315. [Google Scholar] [CrossRef]
- Mizuno, T.; Kawanokuchi, J.; Numata, K.; Suzumura, A. Production and neuroprotective functions of fractalkine in the central nervous system. Brain Res. 2003, 979, 65–70. [Google Scholar] [CrossRef]
- Cardona, A.E.; Pioro, E.P.; Sasse, M.E.; Kostenko, V.; Cardona, S.M.; Dijkstra, I.M.; Huang, D.; Kidd, G.; Dombrowski, S.; Dutta, R.; et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat. Neurosci. 2006, 9, 917–924. [Google Scholar] [CrossRef]
- Sokolowski, J.D.; Chabanon-Hicks, C.N.; Han, C.Z.; Heffron, D.S.; Mandell, J.W. Fractalkine is a “find-me” signal released by neurons undergoing ethanol-induced apoptosis. Front. Cell. Neurosci. 2014, 8, 360. [Google Scholar] [CrossRef]
- Zujovic, V.; Schussler, N.; Jourdain, D.; Duverger, D.; Taupin, V. In vivo neutralization of endogenous brain fractalkine increases hippocampal TNFalpha and 8-isoprostane production induced by intracerebroventricular injection of LPS. J. Neuroimmunol. 2001, 115, 135–143. [Google Scholar] [CrossRef]
- Bachstetter, A.D.; Morganti, J.M.; Jernberg, J.; Schlunk, A.; Mitchell, S.H.; Brewster, K.W.; Hudson, C.E.; Cole, M.J.; Harrison, J.K.; Bickford, P.C.; et al. Fractalkine and CX 3 CR1 regulate hippocampal neurogenesis in adult and aged rats. Neurobiol. Aging 2011, 32, 2030–2044. [Google Scholar] [CrossRef]
- Milinkeviciute, G.; Chokr, S.M.; Castro, E.M.; Cramer, K.S. CX3CR1 mutation alters synaptic and astrocytic protein expression, topographic gradients, and response latencies in the auditory brainstem. J. Comp. Neurol. 2021, 529, 3076–3097. [Google Scholar] [CrossRef]
- Escartin, C.; Galea, E.; Lakatos, A.; O’Callaghan, J.P.; Petzold, G.C.; Serrano-Pozo, A.; Steinhäuser, C.; Volterra, A.; Carmignoto, G.; Agarwal, A.; et al. Reactive astrocyte nomenclature, definitions, and future directions. Nat. Neurosci. 2021, 24, 312–325. [Google Scholar] [CrossRef] [PubMed]
- Escartin, C.; Guillemaud, O.; Carrillo-de Sauvage, M.A. Questions and (some) answers on reactive astrocytes. Glia 2019, 67, 2221–2247. [Google Scholar] [CrossRef]
- Ingelsson, M.; Fukumoto, H.; Newell, K.L.; Growdon, J.H.; Hedley–Whyte, E.T.; Frosch, M.P.; Albert, M.S.; Hyman, B.T.; Irizarry, M.C. Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 2004, 62, 925–931. [Google Scholar] [CrossRef] [PubMed]
- Wruck, W.; Adjaye, J. Meta-analysis of human prefrontal cortex reveals activation of GFAP and decline of synaptic transmission in the aging brain. Acta Neuropathol. Commun. 2020, 8, 26. [Google Scholar] [CrossRef] [PubMed]
- Abdelhak, A.; Foschi, M.; Abu-Rumeileh, S.; Yue, J.K.; D’Anna, L.; Huss, A.; Oeckl, P.; Ludolph, A.C.; Kuhle, J.; Petzold, A.; et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat. Rev. Neurol. 2022, 18, 158–172. [Google Scholar] [CrossRef]
- Aurelian, L.; Balan, I. GABAAR α2-activated neuroimmune signal controls binge drinking and impulsivity through regulation of the CCL2/CX3CL1 balance. Psychopharmacology 2019, 236, 3023–3043. [Google Scholar] [CrossRef]
- Wynne, A.M.; Henry, C.J.; Huang, Y.; Cleland, A.; Godbout, J.P. Protracted downregulation of CX3CR1 on microglia of aged mice after lipopolysaccharide challenge. Brain Behav. Immun. 2010, 24, 1190–1201. [Google Scholar] [CrossRef]
- Balan, I.; Grusca, A.; O’Buckley, T.K.; Morrow, A.L. Neurosteroid [3α,5α]-3-hydroxy-pregnan-20-one enhances IL-10 production via endosomal TRIF-dependent TLR4 signaling pathway. Front. Endocrinol. 2023, 14, 1299420. [Google Scholar] [CrossRef] [PubMed]
- Roche, S.L.; Wyse-Jackson, A.C.; Ruiz-Lopez, A.M.; Byrne, A.M.; Cotter, T.G. Fractalkine-CX3CR1 signaling is critical for progesterone-mediated neuroprotection in the retina. Sci. Rep. 2017, 7, 43067. [Google Scholar] [CrossRef] [PubMed]
- Ruan, C.; Elyaman, W. A New Understanding of TMEM119 as a Marker of Microglia. Front. Cell. Neurosci. 2022, 16, 902372. [Google Scholar] [CrossRef] [PubMed]
- Du, X.; Penalva, R.; Little, K.; Kissenpfennig, A.; Chen, M.; Xu, H. Deletion of Socs3 in LysM+ cells and Cx3cr1 resulted in age-dependent development of retinal microgliopathy. Mol. Neurodegener. 2021, 16, 9. [Google Scholar] [CrossRef] [PubMed]
- Chen, S.; Luo, D.; Streit, W.J.; Harrison, J.K. TGF-beta1 upregulates CX3CR1 expression and inhibits fractalkine-stimulated signaling in rat microglia. J. Neuroimmunol. 2002, 133, 46–55. [Google Scholar] [CrossRef] [PubMed]
- Hopperton, K.E.; Mohammad, D.; Trépanier, M.O.; Giuliano, V.; Bazinet, R.P. Markers of microglia in post-mortem brain samples from patients with Alzheimer’s disease: A systematic review. Mol. Psychiatry 2018, 23, 177–198. [Google Scholar] [CrossRef] [PubMed]
- Chakrabarti, S.; Jana, M.; Roy, A.; Pahan, K. Upregulation of Suppressor of Cytokine Signaling 3 in Microglia by Cinnamic Acid. Curr. Alzheimer Res. 2018, 15, 894–904. [Google Scholar] [CrossRef]
- Gan, A.M.; Butoi, E.; Manea, A.; Pirvulescu, M.M.; Stan, D.; Simion, V.; Calin, M.; Simionescu, M.; Manduteanu, I. Functional analysis of the fractalkine gene promoter in human aortic smooth muscle cells exposed to proinflammatory conditions. FEBS J. 2014, 281, 3869–3881. [Google Scholar] [CrossRef]
- Coraci, I.S.; Husemann, J.; Berman, J.W.; Hulette, C.; Dufour, J.H.; Campanella, G.K.; Luster, A.D.; Silverstein, S.C.; El-Khoury, J.B. CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer’s disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils. Am. J. Pathol. 2002, 160, 101–112. [Google Scholar] [CrossRef]
- Nicolas, S.; Cazareth, J.; Zarif, H.; Guyon, A.; Heurteaux, C.; Chabry, J.; Petit-Paitel, A. Globular Adiponectin Limits Microglia Pro-Inflammatory Phenotype through an AdipoR1/NF-κB Signaling Pathway. Front. Cell. Neurosci. 2017, 11, 352. [Google Scholar] [CrossRef]
- Qu, W.; Li, L. Microglial TREM2 at the Intersection of Brain Aging and Alzheimer’s Disease. Neuroscientist 2023, 29, 302–316. [Google Scholar] [CrossRef] [PubMed]
- Pirvulescu, M.; Manduteanu, I.; Gan, A.M.; Stan, D.; Simion, V.; Butoi, E.; Calin, M.; Simionescu, M. A novel pro-inflammatory mechanism of action of resistin in human endothelial cells: Up-regulation of SOCS3 expression through STAT3 activation. Biochem. Biophys. Res. Commun. 2012, 422, 321–326. [Google Scholar] [CrossRef] [PubMed]
- Beckwith, S.W.; Czachowski, C.L. Alcohol-Preferring P Rats Exhibit Elevated Motor Impulsivity Concomitant with Operant Responding and Self-Administration of Alcohol. Alcohol. Clin. Exp. Res. 2016, 40, 1100–1110. [Google Scholar] [CrossRef] [PubMed]
- Bell, R.L.; Rodd, Z.A.; Lumeng, L.; Murphy, J.M.; McBride, W.J. The alcohol-preferring P rat and animal models of excessive alcohol drinking. Addict. Biol. 2006, 11, 270–288. [Google Scholar] [CrossRef] [PubMed]
- Liu, J.; Yang, A.R.; Kelly, T.; Puche, A.; Esoga, C.; June, H.L., Jr.; Elnabawi, A.; Merchenthaler, I.; Sieghart, W.; June, H.L., Sr.; et al. Binge alcohol drinking is associated with GABAA alpha2-regulated Toll-like receptor 4 (TLR4) expression in the central amygdala. Proc. Natl. Acad. Sci. USA 2011, 108, 4465–4470. [Google Scholar] [CrossRef] [PubMed]
- Balan, I.; Warnock, K.T.; Puche, A.; Gondre-Lewis, M.C.; June, H.; Aurelian, L. The GABAA Receptor α2 Subunit Activates a Neuronal TLR4 Signal in the Ventral Tegmental Area that Regulates Alcohol and Nicotine Abuse. Brain Sci. 2018, 8, 72. [Google Scholar] [CrossRef] [PubMed]
- Bach, P.; Luderer, M.; Müller, U.J.; Jakobs, M.; Baldermann, J.C.; Voges, J.; Kiening, K.; Lux, A.; Visser-Vandewalle, V.; Klosterkötter, J.; et al. Deep brain stimulation of the nucleus accumbens in treatment-resistant alcohol use disorder: A double-blind randomized controlled multi-center trial. Transl. Psychiatry 2023, 13, 49. [Google Scholar] [CrossRef] [PubMed]
- Bracht, T.; Soravia, L.; Moggi, F.; Stein, M.; Grieder, M.; Federspiel, A.; Tschümperlin, R.; Batschelet, H.M.; Wiest, R.; Denier, N. The role of the orbitofrontal cortex and the nucleus accumbens for craving in alcohol use disorder. Transl. Psychiatry 2021, 11, 267. [Google Scholar] [CrossRef]
- Roberto, M.; Kirson, D.; Khom, S. The Role of the Central Amygdala in Alcohol Dependence. Cold Spring Harb. Perspect. Med. 2021, 11, a039339. [Google Scholar] [CrossRef]
- June, H.L.; Liu, J.; Warnock, K.T.; Bell, K.A.; Balan, I.; Bollino, D.; Puche, A.; Aurelian, L. CRF-amplified neuronal TLR4/MCP-1 signaling regulates alcohol self-administration. Neuropsychopharmacology 2015, 40, 1549–1559. [Google Scholar] [CrossRef]
- Dunne, N.; Ivers, J.-H. HPA axis function in alcohol use disorder: A systematic review and meta-analysis. Addict. Neurosci. 2023, 8, 100114. [Google Scholar] [CrossRef]
- Avegno, E.M.; Gilpin, N.W. Reciprocal midbrain-extended amygdala circuit activity in preclinical models of alcohol use and misuse. Neuropharmacology 2022, 202, 108856. [Google Scholar] [CrossRef] [PubMed]
- Mira, R.G.; Lira, M.; Tapia-Rojas, C.; Rebolledo, D.L.; Quintanilla, R.A.; Cerpa, W. Effect of Alcohol on Hippocampal-Dependent Plasticity and Behavior: Role of Glutamatergic Synaptic Transmission. Front. Behav. Neurosci. 2019, 13, 288. [Google Scholar] [CrossRef] [PubMed]
- Sitzia, G.; Lovinger, D.M. Circuit dysfunctions of associative and sensorimotor basal ganglia loops in alcohol use disorder: Insights from animal models. Addict. Neurosci. 2023, 5, 100056. [Google Scholar] [CrossRef] [PubMed]
- Vázquez-León, P.; Miranda-Páez, A.; Chávez-Reyes, J.; Allende, G.; Barragán-Iglesias, P.; Marichal-Cancino, B.A. The Periaqueductal Gray and Its Extended Participation in Drug Addiction Phenomena. Neurosci. Bull. 2021, 37, 1493–1509. [Google Scholar] [CrossRef] [PubMed]
- Belmer, A.; Depoortere, R.; Beecher, K.; Newman-Tancredi, A.; Bartlett, S.E. Neural serotonergic circuits for controlling long-term voluntary alcohol consumption in mice. Mol. Psychiatry 2022, 27, 4599–4610. [Google Scholar] [CrossRef] [PubMed]
- Ogle, T.F.; Kitay, J.I. Ovarian and adrenal steroids during pregnancy and the oestrous cycle in the rat. J. Endocrinol. 1977, 74, 89–98. [Google Scholar] [CrossRef]
- Sze, Y.; Brunton, P.J. Sex, stress and steroids. Eur. J. Neurosci. 2020, 52, 2487–2515. [Google Scholar] [CrossRef]
- Heffner, T.G.; Hartman, J.A.; Seiden, L.S. A rapid method for the regional dissection of the rat brain. Pharmacol. Biochem. Behav. 1980, 13, 453–456. [Google Scholar] [CrossRef]
- Mendelson, W.B.; Martin, J.V.; Perlis, M.; Wagner, R.; Majewska, M.D.; Paul, S.M. Sleep induction by an adrenal steroid in the rat. Psychopharmacology 1987, 93, 226–229. [Google Scholar] [CrossRef]
- Devaud, L.L.; Purdy, R.H.; Morrow, A.L. The neurosteroid, 3α-hydroxy-5α-pregnan-20-one, protects against bicuculline-induced seizures during ethanol withdrawal in rats. Alcohol. Clin. Exp. Res. 1995, 19, 350–355. [Google Scholar] [CrossRef] [PubMed]
- Crawley, J.N.; Glowa, J.R.; Majewska, M.D.; Paul, S.M. Anxiolytic activity of an endogenous adrenal steroid. Brain Res. 1986, 398, 382–385. [Google Scholar] [CrossRef] [PubMed]
- Inoue, K.; Morimoto, H.; Ohgidani, M.; Ueki, T. Modulation of inflammatory responses by fractalkine signaling in microglia. PLoS ONE 2021, 16, e0252118. [Google Scholar] [CrossRef] [PubMed]
- Jurga, A.M.; Paleczna, M.; Kuter, K.Z. Overview of General and Discriminating Markers of Differential Microglia Phenotypes. Front. Cell. Neurosci. 2020, 14, 198. [Google Scholar] [CrossRef] [PubMed]
- Gomes, F.C.; Paulin, D.; Moura Neto, V. Glial fibrillary acidic protein (GFAP): Modulation by growth factors and its implication in astrocyte differentiation. Braz. J. Med. Biol. Res. 1999, 32, 619–631. [Google Scholar] [CrossRef] [PubMed]
- Mercurio, D.; Fumagalli, S.; Schafer, M.K.; Pedragosa, J.; Ngassam, L.D.C.; Wilhelmi, V.; Winterberg, S.; Planas, A.M.; Weihe, E.; De Simoni, M.G. Protein Expression of the Microglial Marker Tmem119 Decreases in Association with Morphological Changes and Location in a Mouse Model of Traumatic Brain Injury. Front. Cell. Neurosci. 2022, 16, 820127. [Google Scholar] [CrossRef] [PubMed]
- Yeo, H.G.; Hong, J.J.; Lee, Y.; Yi, K.S.; Jeon, C.Y.; Park, J.; Won, J.; Seo, J.; Ahn, Y.J.; Kim, K.; et al. Increased CD68/TGFβ Co-expressing Microglia/ Macrophages after Transient Middle Cerebral Artery Occlusion in Rhesus Monkeys. Exp. Neurobiol. 2019, 28, 458–473. [Google Scholar] [CrossRef]
- Yang, J.; Fu, Z.; Zhang, X.; Xiong, M.; Meng, L.; Zhang, Z. TREM2 ectodomain and its soluble form in Alzheimer’s disease. J. Neuroinflamm. 2020, 17, 204. [Google Scholar] [CrossRef]
- Takahashi, K.; Rochford, C.D.; Neumann, H. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J. Exp. Med. 2005, 201, 647–657. [Google Scholar] [CrossRef]
- Dobri, A.-M.; Dudău, M.; Enciu, A.-M.; Hinescu, M.E. CD36 in Alzheimer’s Disease: An Overview of Molecular Mechanisms and Therapeutic Targeting. Neuroscience 2021, 453, 301–311. [Google Scholar] [CrossRef]
- Song, J.; Choi, S.M.; Kim, B.C. Adiponectin Regulates the Polarization and Function of Microglia via PPAR-γ Signaling Under Amyloid β Toxicity. Front. Cell. Neurosci. 2017, 11, 64. [Google Scholar] [CrossRef] [PubMed]
- Yang, J.; Ran, M.; Li, H.; Lin, Y.; Ma, K.; Yang, Y.; Fu, X.; Yang, S. New insight into neurological degeneration: Inflammatory cytokines and blood-brain barrier. Front. Mol. Neurosci. 2022, 15, 1013933. [Google Scholar] [CrossRef] [PubMed]
- Sheridan, G.K.; Wdowicz, A.; Pickering, M.; Watters, O.; Halley, P.; O’Sullivan, N.C.; Mooney, C.; O’Connell, D.J.; O’Connor, J.J.; Murphy, K.J. CX3CL1 is up-regulated in the rat hippocampus during memory-associated synaptic plasticity. Front. Cell. Neurosci. 2014, 8, 233. [Google Scholar] [CrossRef] [PubMed]
- Kawamura, N.; Katsuura, G.; Yamada-Goto, N.; Novianti, E.; Inui, A.; Asakawa, A. Reduced brain fractalkine-CX3CR1 signaling is involved in the impaired cognition of streptozotocin-treated mice. IBRO Rep. 2020, 9, 233–240. [Google Scholar] [CrossRef]
- Réaux-Le Goazigo, A.; Van Steenwinckel, J.; Rostène, W.; Mélik Parsadaniantz, S. Current status of chemokines in the adult CNS. Prog. Neurobiol. 2013, 104, 67–92. [Google Scholar] [CrossRef] [PubMed]
- Imaizumi, T.; Yoshida, H.; Satoh, K. Regulation of CX3CL1/Fractalkine Expression in Endothelial Cells. J. Atheroscler. Thromb. 2004, 11, 15–21. [Google Scholar] [CrossRef] [PubMed]
- Morrow, A.L.; Boero, G.; Balan, I. Emerging Evidence for Endogenous Neurosteroid Modulation of Pro-Inflammatory and Anti-Inflammatory Pathways that Impact Neuropsychiatric Disease. Neurosci. Biobehav. Rev. 2024, 158, 105558. [Google Scholar] [CrossRef] [PubMed]
- Yan, Z.; Yang, W.; Parkitny, L.; Gibson, S.A.; Lee, K.S.; Collins, F.; Deshane, J.S.; Cheng, W.; Weinmann, A.S.; Wei, H.; et al. Deficiency of Socs3 leads to brain-targeted EAE via enhanced neutrophil activation and ROS production. JCI Insight 2019, 5, e126520. [Google Scholar] [CrossRef] [PubMed]
- Turbitt, W.J.; Yan, Z.; Yang, W.; Buckley, J.; Zhou, L.; Qin, H.; Benveniste, E. Neutrophil-specific Socs3 deficiency induces brain-targeted experimental autoimmune encephalomyelitis with increased cerebellar neutrophils. J. Immunol. 2021, 206, 60.07. [Google Scholar] [CrossRef]
- Cassatella, M.A.; Gasperini, S.; Bovolenta, C.; Calzetti, F.; Vollebregt, M.; Scapini, P.; Marchi, M.; Suzuki, R.; Suzuki, A.; Yoshimura, A. Interleukin-10 (IL-10) Selectively Enhances CIS3/SOCS3 mRNA Expression in Human Neutrophils: Evidence for an IL-10–Induced Pathway That Is Independent of STAT Protein Activation. Blood 1999, 94, 2880–2889. [Google Scholar] [CrossRef]
- Cevey, Á.C.; Penas, F.N.; Alba Soto, C.D.; Mirkin, G.A.; Goren, N.B. IL-10/STAT3/SOCS3 Axis Is Involved in the Anti-inflammatory Effect of Benznidazole. Front. Immunol. 2019, 10, 1267. [Google Scholar] [CrossRef] [PubMed]
- Nichols, N.R.; Day, J.R.; Laping, N.J.; Johnson, S.A.; Finch, C.E. GFAP mRNA increases with age in rat and human brain. Neurobiol. Aging 1993, 14, 421–429. [Google Scholar] [CrossRef] [PubMed]
- Antignano, I.; Liu, Y.; Offermann, N.; Capasso, M. Aging microglia. Cell Mol. Life Sci. 2023, 80, 126. [Google Scholar] [CrossRef] [PubMed]
- Bernardi, F.; Salvestroni, C.; Casarosa, E.; Nappi, R.E.; Lanzone, A.; Luisi, S.; Purdy, R.H.; Petraglia, F.; Genazzani, A.R. Aging is associated with changes in allopregnanolone concentrations in brain, endocrine glands and serum in male rats. Eur. J. Endocrinol. 1998, 138, 316–321. [Google Scholar] [CrossRef] [PubMed]
- Balan, I.; Boero, G.; Chéry, S.L.; McFarland, M.H.; Lopez, A.G.; Morrow, A.L. Neuroactive Steroids, Toll-like Receptors, and Neuroimmune Regulation: Insights into Their Impact on Neuropsychiatric Disorders. Life 2024, 14, 582. [Google Scholar] [CrossRef] [PubMed]
- von Boyen, G.B.; Steinkamp, M.; Reinshagen, M.; Schäfer, K.H.; Adler, G.; Kirsch, J. Proinflammatory cytokines increase glial fibrillary acidic protein expression in enteric glia. Gut 2004, 53, 222–228. [Google Scholar] [CrossRef]
- Wang, T.; Chen, S.; Mao, Z.; Shang, Y.; Brinton, R.D. Allopregnanolone pleiotropic action in neurons and astrocytes: Calcium signaling as a unifying mechanism. Front. Endocrinol. 2023, 14, 1286931. [Google Scholar] [CrossRef]
- Lee, Y.B.; Du, S.; Rhim, H.; Lee, E.B.; Markelonis, G.J.; Oh, T.H. Rapid increase in immunoreactivity to GFAP in astrocytes in vitro induced by acidic pH is mediated by calcium influx and calpain I. Brain Res. 2000, 864, 220–229. [Google Scholar] [CrossRef]
- Colciago, A.; Magnaghi, V. Neurosteroids Involvement in the Epigenetic Control of Memory Formation and Storage. Neural Plast. 2016, 2016, 5985021. [Google Scholar] [CrossRef]
- Kumar, P.; Godbole, N.M.; Chaturvedi, C.P.; Singh, R.S.; George, N.; Upadhyay, A.; Anjum, B.; Godbole, M.M.; Sinha, R.A. Mechanisms involved in epigenetic down-regulation of Gfap under maternal hypothyroidism. Biochem. Biophys. Res. Commun. 2018, 502, 375–381. [Google Scholar] [CrossRef]
Target | Catalog Number | Commercial Supplier | Clonality | Host | Dilution |
---|---|---|---|---|---|
CX3CL1 | 14-7986-81 | Thermo Fisher Scientific, Waltham, MA, USA | Polyclonal | Rabbit | 1:100/IHC |
CX3CR1 | 14-6093-81 | Thermo Fisher Scientific, Waltham, MA, USA | Polyclonal | Rabbit | 1:1000/IB |
Phospho-STAT1 | 9177 | Cell Signaling Technology, Danvers, MA, USA | Polyclonal | Rabbit | 1:1000/IB |
TGF-β1 | 21898-1-AP | Proteintech Group, Rosemont, IL, USA | Polyclonal | Rabbit | 1:2000/IB |
GFAP | Z033429-2 | Agilent Technologies/Dako, Santa Clara, CA, USA | Polyclonal | Rabbit | 1:1000/IB |
GFAP | ab4648 | Abcam Inc, Cambridge, MA, USA | Monoclonal | Mouse | 1:500/IHC |
IBA1 | MA5-27726 | Thermo Fisher Scientific, Waltham, MA, USA | Monoclonal | Mouse | 1:500/IB |
TMEM119 | 400 211 | Synaptic Systems GmbH, Goettingen, Germany | Monoclonal | Mouse | 1:500/IB; 1:500/IHC |
SOCS3 | sc-73045 | Santa Cruz Biotechnology, Santa Cruz, CA, USA | Monoclonal | Mouse | 1:200/IB |
CD68 | MCA341R | Bio-Rad Laboratories, Hercules, CA, USA | Monoclonal | Mouse | 1:300/IB |
CD36 | sc-7309 | Santa Cruz Biotechnology, Santa Cruz, CA, USA | Monoclonal | Mouse | 1:200/IB |
Acrp30 | sc-136131 | Santa Cruz Biotechnology, Santa Cruz, CA, USA | Monoclonal | Mouse | 1:200/IB |
TREM-2 | sc-373828 | Santa Cruz Biotechnology, Santa Cruz, CA, USA | Monoclonal | Mouse | 1:200/IB |
NeuN | MAB377 | Sigma-Aldrich, St. Louis, MO, USA | Monoclonal | Mouse | 1:500/IHC |
β-Actin | 66009-1-Ig | Proteintech Group, Rosemont, IL, USA | Monoclonal | Mouse | 1:3000/IB |
Brain Area | 3α,5α-THP vs. Vehicle (Mean ± SEM; pg/mg) Unpaired t-test: t-Value, Degrees of Freedom (df), Significance Level (p-Value) | |
---|---|---|
Females | Males | |
NAc | 1984 ± 88.2 vs. 1716 ± 52.4 | 2430 ± 147.0 vs. 2450 ± 85.6 |
Upregulation: +15.6 ± 5.9% | No difference | |
t-test: t = 2.61, df = 18, p = 0.02 * | t-test: t = 0.12, df = 18, p = 0.91 | |
Amygdala | 2635 ± 134.0 vs. 2001 ± 64.9 | 2579 ± 123.4 vs. 2380 ± 125.7 |
Upregulation: +31.7 ± 7.4% | No difference | |
t-test: t = 4.26, df = 18, p = 0.0002 *** | t-test: t = 1.13, df = 18, p = 0.27 | |
Midbrain | 1150 ± 52.8 vs. 937.9 ± 36.2 | 1118 ± 32.6 vs. 1124 ± 29.7 |
Upregulation: +22.6 ± 6.8% | No difference | |
t-test: t = 3.31, df = 18, p = 0.004 ** | t-test: t = 0.13, df = 18, p = 0.90 | |
Hypothalamus | 1031 ± 21.1 vs. 838 ± 45.9 | 872.5 ± 54.1 vs. 929.9 ± 38.7 |
Upregulation: +23.1 ± 6.0% | No difference | |
t-test: t = 3.83, df = 18, p = 0.002 ** | t-test: t = 0.80, df = 18, p = 0.46 | |
VTA | 2103 ± 211.3 vs. 1828 ± 153.3 | 1618 ± 61.5 vs. 1757 ± 157.2 |
No difference | No difference | |
t-test: t = 1.0, df = 18, p = 0.35 | t-test: t = 0.82, df = 18, p = 0.42 | |
Hippocampus | 1567 ± 171.4 vs. 1473 ± 109.6 | 1721 ± 92.5 vs. 1876 ± 169.1 |
No difference | No difference | |
t-test: t = 0.43, df = 18, p = 0.68 | t-test: t = 0.86, df = 18, p = 0.43 | |
Striatum | 1930 ± 140.2 vs. 2175 ± 208.5 | 1971 ± 199.5 vs. 1922 ± 232.2 |
No difference | No difference | |
t-test: t = 1.0, df = 18, p = 0.35 | t-test: t = 0.16, df = 18, p = 0.88 |
Marker | Percentage (%) Change Following 3α,5α-THP Administration vs. Vehicle Control Unpaired t-Test: t-Value, Degrees of Freedom (df), Significance Level (p-Value) Mann–Whitney Test: U-Value, Significance Level (p-Value), Sample Size (n) | |
---|---|---|
NAc Females | NAc Males | |
IBA1 | No difference | No difference |
t = 0.66, df = 18, p = 0.52 | U = 26, p = 0.08, n = 10 | |
TMEM119 | No difference | No difference |
t = 1.00, df = 18, p = 0.33 | t = 0.96, df = 18, p = 0.35 | |
CD68 | No difference | No difference |
t = 1.53, df = 18, p = 0.14 | t = 1.75, df = 18, p = 0.10 | |
CD36 | No difference | No difference |
t = 0.08, df = 18, p = 0.94 | t = 1.34, df = 18, p = 0.27 | |
TREM-2 | No difference | No difference |
t = 1.99, df = 18, p = 0.06 | t = 1.24, df = 18, p = 0.23 | |
Acrp30 | No difference | No difference |
t = 0.16, df = 18, p = 0.88 | t = 0.53, df = 18, p = 0.60 | |
SOCS3 | No difference | Upregulation: +27.4 ± 11.7% |
t = 0.38, df = 18, p = 0.71 | t = 2.35, df = 18, p = 0.03 * |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Balan, I.; Grusca, A.; Chéry, S.L.; Materia, B.R.; O’Buckley, T.K.; Morrow, A.L. Neurosteroid [3α,5α]-3-Hydroxy-pregnan-20-one Enhances the CX3CL1-CX3CR1 Pathway in the Brain of Alcohol-Preferring Rats with Sex-Specificity. Life 2024, 14, 860. https://doi.org/10.3390/life14070860
Balan I, Grusca A, Chéry SL, Materia BR, O’Buckley TK, Morrow AL. Neurosteroid [3α,5α]-3-Hydroxy-pregnan-20-one Enhances the CX3CL1-CX3CR1 Pathway in the Brain of Alcohol-Preferring Rats with Sex-Specificity. Life. 2024; 14(7):860. https://doi.org/10.3390/life14070860
Chicago/Turabian StyleBalan, Irina, Adelina Grusca, Samantha Lucenell Chéry, Baylee R. Materia, Todd K. O’Buckley, and A. Leslie Morrow. 2024. "Neurosteroid [3α,5α]-3-Hydroxy-pregnan-20-one Enhances the CX3CL1-CX3CR1 Pathway in the Brain of Alcohol-Preferring Rats with Sex-Specificity" Life 14, no. 7: 860. https://doi.org/10.3390/life14070860